HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
UHS
Universal Health Services, Inc.
UHS's fundamentals are mixed, but it looks cheap: trading at 8.1x earnings, below its usual 12x. Analysts expect earnings to hold roughly steady.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
UHS Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Healthy | |
| Stable |
UHS's profitability and cash flow are currently healthy, and its revenue and balance sheet are stable.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
UHS PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8.1x | $194 | — |
| Forward | 8.6x | $194 | — |
| Cheap | 9.7x | $231 | +19% |
| Fair | 12x | $296 | +53% |
| Expensive | 15x | $367 | +89% |
Historical ranges are pointers, not guarantees.
UHS's PE is in its cheap range at 8.1x. On analysts' estimates for next year's earnings, today's price would be 8.6x.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
UHS Forward outlook
| Metric | Outlook |
|---|---|
| Deteriorating | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect UHS's revenue to grow, but its profitability to weaken.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
UHS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $22.52 | -5.6% |
| Q3 2026 | $23.86 | +13% |
| Q2 2026 | $24.50 | +29% |
| Q1 2026 | $23.95 | +35% |
| Q4 2025 | $23.10 | +37% |
| Q3 2025 | $21.03 | +40% |
| Q2 2025 | $18.97 | +39% |
| Q1 2025 | $17.80 | +51% |
| Q4 2024 | $16.82 | +64% |
UHS has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over UHS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
UHS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $4.7B | +5.3% |
| Q2 2026 | $4.6B | +8.3% |
| Q1 2026 | $4.5B | +9.6% |
| Q4 2025 | $4.5B | +9.1% |
| Q3 2025 | $4.5B | +13% |
| Q2 2025 | $4.3B | +9.6% |
| Q1 2025 | $4.1B | +6.7% |
| Q4 2024 | $4.1B | +11% |
UHS's revenue has grown year over year every quarter since late 2020: $4.7B last quarter, up 5.3% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.6% | -2 points |
| Q2 2026 | 11% | -0.5 points |
| Q1 2026 | 11% | +0.1 points |
| Q4 2025 | 12% | 0 points |
| Q3 2025 | 12% | +1.9 points |
| Q2 2025 | 12% | +0.5 points |
| Q1 2025 | 11% | +1 points |
| Q4 2024 | 11% | +2.6 points |
UHS has the edge over HIMS on profitability, with a higher operating margin.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over UHS on cash flow, with more consistent year-over-year improvement.
UHS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $421.6M | +178% |
| Q2 2026 | $215.7M | -24% |
| Q1 2026 | $184.5M | +52% |
| Q4 2025 | $293.5M | -29% |
| Q3 2025 | $151.8M | +78% |
| Q2 2025 | $283M | -35% |
| Q1 2025 | $121M | -36% |
| Q4 2024 | $412.5M | +68% |
UHS still generates free cash flow, though less than at its 2020 peak: $1.1B over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has 234M diluted shares, down 6% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
UHS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -765K shares |
| 1 year | -7.1% | -4.5M shares |
| 3 years | -15% | -10.5M shares |
| 5 years | -29% | -24.5M shares |
| Available history | -34% | -29.9M shares |
UHS has the edge over HIMS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $245.3M |
| Q2 2026 | $320.8M |
| Q1 2026 | $163.8M |
| Q4 2025 | $352M |
| Q3 2025 | $237.4M |
| Q2 2025 | $155.2M |
| Q1 2025 | $223.4M |
| Q4 2024 | $250.2M |
UHS spent $1.1B buying back its own shares over the past year, up 25% from the year before.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
UHS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 2.1x | Moderate |
| Q2 2026 | 1.8x | Healthy |
| Q1 2026 | 1.7x | Healthy |
| Q4 2025 | 1.8x | Healthy |
| Q3 2025 | 1.8x | Healthy |
| Q2 2025 | 1.9x | Healthy |
| Q1 2025 | 1.9x | Healthy |
| Q4 2024 | 1.9x | Healthy |
UHS's net debt is about 2.1 years of its operating earnings (EBITDA), up from 1.8 years a year ago.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
UHS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 60.4 | Neutral |
| Stochastic | 71.1 | Neutral |
UHS's weekly RSI is 60 (neutral) and its Stochastic is 71 (neutral).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
UHS PE vs Healthcare Sector
| Metric | UHS | Sector median | Relative |
|---|---|---|---|
| PE | 8.1x | 26x | 69% below |
| PE % | 9 | 29 | 20 pts below |
UHS is trading at 8.1x earnings, a 69% discount to the Healthcare sector's median of 26x.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
UHS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $183.7 | 5.5% above |
| 20 week MA | $173.6 | 12% above |
| 50 week MA | $183.2 | 5.8% above |
| 100 week MA | $185.2 | 4.7% above |
| 200 week MA | $174.6 | 11% above |
UHS has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
UHS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $143.4 | $136.9 | -4.5% |
| 2021 | $136.9 | $128.1 | -6.4% |
| 2022 | $128.1 | $140.8 | +9.9% |
| 2023 | $140.8 | $152.4 | +8.3% |
| 2024 | $152.4 | $180.5 | +18% |
| 2025 | $180.5 | $227.6 | +26% |
| 2026 YTD | $227.6 | $193.8 | -15% |
UHS has the edge over HIMS on returns for 2026, with the stronger performance.